Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and invasive mucormycosis. Basilea is publicly traded on the SIX Swiss exchange (SIX: BSLIN).
The company is based in Basel, Switzerland. It has subsidiaries in France (Basilea Pharmaceuticals SAS), Germany (Basilea Pharmaceuticals GmbH), Denmark (Basilea Pharmaceuticals A/S), the People's Republic of China (Basilea Pharmaceutica China Ltd), Spain (Basilea Pharmaceuticals Iberia SL), the United Kingdom (Basilea Pharmaceuticals Ltd.), and the United States of America (Basilea Pharmaceuticals Inc.). According to stock filings, it had 196 employees as of June 2007.Among the company’s notable products is Isavuconazole (CRESEMBA) an intravenous and oral antifungal, received orphan drug status designation by the United States Food and Drug Administration (FDA) in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus.